<table cellpadding="0.1pt" cellspacing="0pt" id="_RefTable_5" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 5 Drug Interactions: Changes in Pharmacokinetic Parameters for Co-administered Drug in the Presence of Nevirapine (All interaction trials were conducted in HIV-1 positive subjects)</caption>
<col width="21%"></col>
<col width="16%"></col>
<col width="13%"></col>
<col width="12%"></col>
<col width="13%"></col>
<col width="13%"></col>
<col width="13%"></col>
<tfoot>
<tr>
<td align="left" colspan="7" stylecode="Botrule" valign="top">§ = C<sub>min</sub> below detectable level of the assay<br/>↑ = Increase, ↓ = Decrease, ⇔ = No Effect<br/>
<sup>a</sup> For information regarding clinical recommendations, see <content stylecode="italics">Drug Interactions <linkhtml href="#Section_7">(7)</linkhtml>
</content>.<br/>
<sup>b</sup> Pediatric subjects ranging in age from 6 months to 12 years <br/>
<sup>c</sup> Parallel group design; n for nevirapine+lopinavir/ritonavir, n for lopinavir/ritonavir alone.<br/>
<sup>d</sup> Parallel group design; n=23 for atazanavir/ritonavir + nevirapine, n=22 for atazanavir/ritonavir without nevirapine. Changes in atazanavir PK are relative to atazanavir/ritonavir 300/100 mg alone.<br/>
<sup>e</sup> Based on between-trial comparison.<br/>
<sup>f</sup> Based on historical controls.</td>
</tr>
</tfoot>
<tbody>
<tr>
<td stylecode="Botrule Lrule Toprule ">
<paragraph>
<content stylecode="bold">Co-administered Drug</content>
</paragraph>
</td>
<td stylecode="Botrule Lrule Toprule ">
<paragraph>
<content stylecode="bold">Dose of Co-administered Drug</content>
</paragraph>
</td>
<td stylecode="Botrule Lrule Toprule ">
<paragraph>
<content stylecode="bold">Dose Regimen of Nevirapine</content>
</paragraph>
</td>
<td stylecode="Botrule Lrule Toprule ">
<paragraph>
<content stylecode="bold">n</content>
</paragraph>
</td>
<td colspan="3" stylecode="Rrule Botrule Lrule Toprule ">
<paragraph>
<content stylecode="bold">% Change of Co-administered Drug Pharmacokinetic Parameters (90% CI)</content>
</paragraph>
</td>
</tr>
<tr>
<td colspan="4" stylecode="Rrule Lrule ">
<paragraph>
<content stylecode="bold">Antiretrovirals</content>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>
<content stylecode="bold">AUC</content>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>
<content stylecode="bold">C<sub>max</sub>
</content>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>
<content stylecode="bold">C<sub>min</sub>
</content>
</paragraph>
</td>
</tr>
<tr>
<td rowspan="2" stylecode="Rrule Lrule ">
<paragraph>Atazanavir/Ritonavir<sup>a, d</sup>
</paragraph>
</td>
<td rowspan="2" stylecode="Rrule ">
<paragraph>300/100 mg QD<br/>day 4–13, then 400/100 mg QD, day 14–23</paragraph>
</td>
<td rowspan="2" stylecode="Rrule ">
<paragraph>200 mg BID day 1-23. Subjects were treated with nevirapine prior to trial entry.</paragraph>
</td>
<td rowspan="2" stylecode="Rrule ">
<paragraph>23</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>
<content stylecode="underline">Atazanavir</content>
<br/>
<content stylecode="underline">300/100 mg</content>
<br/>
<br/>↓42<br/>(↓52 to ↓29)<br/>
<br/>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>
<content stylecode="underline">Atazanavir</content>
<br/>
<content stylecode="underline">300/100 mg </content>
<br/>
<br/>↓28<br/>(↓40 to ↓14)<br/>
<br/>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>
<content stylecode="underline">Atazanavir</content>
<br/>
<content stylecode="underline">300/100 mg </content>
<br/>
<br/>↓72<br/>(↓80 to ↓60)<br/>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule ">
<paragraph>
<content stylecode="underline">Atazanavir</content>
<br/>
<content stylecode="underline">400/100 mg</content>
<br/>
<br/>↓19<br/> (↓35 to ↑2)<br/>
<br/>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>
<content stylecode="underline">Atazanavir</content>
<br/>
<content stylecode="underline">400/100 mg</content>
<br/>
<br/>↑2<br/>(↓15 to ↑24)<br/>
<br/>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>
<content stylecode="underline">Atazanavir</content>
<br/>
<content stylecode="underline">400/100 mg</content>
<br/>
<br/>↓59 <br/>(↓73 to ↓40)<br/>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Darunavir/Ritonavir <sup>e</sup>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>400/100 mg BID</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>200 mg BID</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>8</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↑24 <br/>(↓3 to ↑57)<br/>
<br/>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↑40 <br/>(↑14 to ↑73)<br/>
<br/>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↑2 <br/>(↓21 to ↑32)<br/>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Didanosine</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>100-150 mg BID</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>18</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>⇔</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>⇔</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>§</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Efavirenz<sup>a</sup>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>600 mg QD</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>200 mg QD x 14 days; 400 mg QD x 14 days</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>17</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓28<br/>(↓34 to ↓14)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓12<br/>(↓23 to ↑1)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓32<br/>(↓35 to ↓19)</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Fosamprenavir</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>1400 mg BID</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>200 mg BID.  Subjects were treated with nevirapine prior to trial entry.</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>17</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓33 <br/>(↓45 to ↓20)<br/>
<br/>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓25 <br/>(↓37 to ↓10)<br/>
<br/>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓35  <br/>(↓50 to ↓15)<br/>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Fosamprenavir/Ritonavir</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>700/100 mg BID</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>200 mg BID.  Subjects were treated with nevirapine prior to trial entry</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>17</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓11<br/>(↓23 to ↑3)<br/>
<br/>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>⇔<br/>
<br/>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓19 <br/>(↓32 to ↓4)<br/>
<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Indinavir<sup>a</sup>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>800 mg q8H</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>19</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓31<br/>(↓39 to ↓22)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓15<br/>(↓24 to ↓4)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓44<br/>(↓53 to ↓33)</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Lopinavir<sup>a, b</sup>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>300/75 mg/m<sup>2</sup> (lopinavir/<br/>ritonavir) <sup>b</sup>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>7 mg/kg or 4 mg/kg QD x 2 weeks; BID x 1 week</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>12, 15 <sup>c</sup>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓22<br/>(↓44 to ↑9)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓14<br/>(↓36 to ↑16)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓55<br/>(↓75 to ↓19)</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Lopinavir<sup>a</sup>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>400/100 mg BID (lopinavir/ritonavir)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID &gt;1 year</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>22, 19 <sup>c</sup>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓27<br/>(↓47 to ↓2)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓19<br/>(↓38 to ↑5)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓51<br/>(↓72 to ↓26)</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Maraviroc <sup>f</sup>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>300 mg SD</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>200 mg BID</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>8</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↑1 <br/>(↓35 to ↑55)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↑54 <br/>(↓6 to ↑151)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>⇔ </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Nelfinavir<sup>a</sup>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>750 mg TID</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>23</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>⇔</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>⇔</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓32<br/>(↓50 to ↑5)</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Nelfinavir-M8 metabolite</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph> </paragraph>
</td>
<td stylecode="Rrule ">
<paragraph> </paragraph>
</td>
<td stylecode="Rrule ">
<paragraph> </paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓62<br/>(↓70 to ↓53)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓59<br/>(↓68 to ↓48)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓66<br/>(↓74 to ↓55)</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Ritonavir</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>600 mg BID</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>18</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>⇔</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>⇔</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>⇔</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Stavudine</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>30-40 mg BID</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>22</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>⇔</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>⇔</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>§</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Zalcitabine</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>0.125-0.25 mg TID</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>6</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>⇔</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>⇔</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>§</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Zidovudine</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>100-200 mg TID</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>11</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓28<br/>(↓40 to ↓4)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓30<br/>(↓51 to ↑14)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>§</paragraph>
</td>
</tr>
<tr>
<td colspan="4" stylecode="Rrule Lrule ">
<paragraph>
<content stylecode="bold">Other Medications</content>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>
<content stylecode="bold">AUC</content>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>
<content stylecode="bold">C<sub>max</sub>
</content>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>
<content stylecode="bold">C<sub>min</sub>
</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Clarithromycin<sup>a</sup>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>500 mg BID</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>15</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓31<br/>(↓38 to ↓24)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓23<br/>(↓31 to ↓14)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓56<br/>(↓70 to ↓36)</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Metabolite <br/>14-OH-clarithromycin</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph> </paragraph>
</td>
<td stylecode="Rrule ">
<paragraph> </paragraph>
</td>
<td stylecode="Rrule ">
<paragraph> </paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↑42<br/>(↑16 to ↑73)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↑47<br/>(↑21 to ↑80)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>⇔</paragraph>
</td>
</tr>
<tr>
<td rowspan="2" stylecode="Rrule Lrule ">
<paragraph>Ethinyl estradiol<sup>a</sup>
<br/>
<br/>and<br/>
<br/>Norethindrone<sup>a</sup>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>0.035 mg<br/>(as Ortho-Novum<sup>®</sup> 1/35)</paragraph>
</td>
<td rowspan="2" stylecode="Rrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days</paragraph>
</td>
<td rowspan="2" stylecode="Rrule ">
<paragraph>
<br/>10</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓20<br/>(↓33 to ↓3)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>⇔</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>§</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule ">
<paragraph>1 mg<br/>(as Ortho-Novum<sup>®</sup> 1/35)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓19<br/>(↓30 to ↓7)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓16<br/>(↓27 to ↓3)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>§</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Depomedroxy-progesterone acetate</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>150 mg every 3 months</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>32</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>⇔</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>⇔</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>⇔</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Fluconazole</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>200 mg QD</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>19</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>⇔</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>⇔</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>⇔</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Ketoconazole<sup>a</sup>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>400 mg QD</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>21</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓72<br/>(↓80 to ↓60)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↓44<br/>(↓58 to ↓27)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>§</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Methadone<sup>a</sup>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>Individual Subject Dosing</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID ≥7 days</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>9</paragraph>
</td>
<td colspan="3" stylecode="Rrule ">
<paragraph>In a controlled pharmacokinetic trial with 9 subjects receiving chronic methadone to whom steady-state nevirapine therapy was added, the clearance of methadone was increased by 3-fold, resulting in symptoms of withdrawal, requiring dose adjustments in 10 mg segments, in 7 of the 9 subjects. Methadone did not have any effect on nevirapine clearance.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Rifabutin<sup>a</sup>
</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>150 or 300 mg QD</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>19</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↑17<br/>(↓2 to ↑40)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↑28<br/>(↑9 to ↑51)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>⇔</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule ">
<paragraph>Metabolite<br/>25-O-desacetyl-rifabutin</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph> </paragraph>
</td>
<td stylecode="Rrule ">
<paragraph> </paragraph>
</td>
<td stylecode="Rrule ">
<paragraph> </paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↑24<br/>(↓16 to ↑84)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↑29<br/>(↓2 to ↑68)</paragraph>
</td>
<td stylecode="Rrule ">
<paragraph>↑22<br/>(↓14 to ↑74)</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule Lrule ">
<paragraph>Rifampin<sup>a</sup>
</paragraph>
</td>
<td stylecode="Rrule Botrule ">
<paragraph>600 mg QD</paragraph>
</td>
<td stylecode="Rrule Botrule ">
<paragraph>200 mg QD x 14 days; 200 mg BID x 14 days</paragraph>
</td>
<td stylecode="Rrule Botrule ">
<paragraph>14</paragraph>
</td>
<td stylecode="Rrule Botrule ">
<paragraph>↑11<br/>(↓4 to ↑28)</paragraph>
</td>
<td stylecode="Rrule Botrule ">
<paragraph>⇔</paragraph>
</td>
<td stylecode="Rrule Botrule ">
<paragraph>§</paragraph>
</td>
</tr>
</tbody>
</table>